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Abstract: Preoperative localisation of the diseased parathyroid gland(s) in primary hyperparathyroidism
(PHP) is a prerequisite for subsequent minimally invasive surgery. Recently, as alternatives to
conventional sestamibi parathyroid scintigraphy, the 11C-based positron emission tomography
(PET) tracers methionine and choline have shown promise for this purpose. We evaluated the
feasibility of using the 18F-based PET tracer fluoroethyl-L-tyrosine (FET), as the longer half-life of 18F
makes it logistically more favourable. As a proof-of-concept study, we included two patients with
PHP in which dual-isotope parathyroid subtraction single photon emission computed tomography
had determined the exact location of the parathyroid adenoma. A dynamic FET PET/CT
scan was performed with subsequent visual evaluation and calculation of target-to-background
(TBR; parathyroid vs. thyroid). The maximum TBR in the two patients under study was achieved
approximately 30 min after the injection of the tracer and was 1.5 and 1.7, respectively. This ratio was
too small to allow for confident visualisation of the adenomas. FET PET/CT seems not feasible as
a preoperative imaging modality in PHP.
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1. Introduction
In primary hyperparathyroidism (PHP), excessive secretion of parathyroid hormone (PTH) from
one or more hyperactive parathyroid glands causes elevated levels of blood Ca2+. In approximately
90% of cases, PHP is caused by a single parathyroid adenoma. The preferred treatment is surgical
removal of the diseased gland(s). As the location of the parathyroid adenoma is variable, preoperative
imaging is often performed in order to permit a minimally-invasive surgical approach. Current imaging
modalities include ultrasonography, parathyroid scintigraphy, contrast-enhanced CT, and magnetic
resonance imaging. Recently, positron emission tomography/CT (PET/CT) using the 11C-labelled
amino acid derivative [11C-L-methyl]-methionine (MET) and the 11C-labelled vitamin-like choline has
shown promise. However, the availability of the 11C-based tracers is limited because the short half-life
of 11C (20 min) requires an on-site cyclotron. In our department, we routinely use the 18F-based tracer
O-2-(18F)fluoroethyl-L-tyrosine (FET)—another amino acid derivative—for brain glioma imaging.
The 18F-based PET tracers are much easier to handle and distribute due to the longer half-life of 2 h,
and they also provide better spatial resolution due to a shorter positron range, thus making them more
appealing for diagnostic use. We considered it likely that FET would perform comparably to MET,
as both are amino acid derivatives.
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Therefore, we carried out a “proof-of-concept” study in two patients, aiming to verify or refute
the feasibility of further evaluation of FET-PET in the preoperative workup in PHP.
2. Results
Only faint FET uptake was detected in both thyroid tissue and the parathyroid adenomas
(Figure 1). Excluding an obvious vascular phase during the first 10 min, TBRmax (for definition
please refer to Materials and Methods) was reached between 30 and 35 min post-injection. TBRmax in
patients (a) and (b) was 1.5 and 1.7, respectively. Thus, no clinically relevant differential uptake of FET
could be detected in the parathyroid adenomas in either of the two patients (Figure 2).
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Figure 1. Tracer-uptake in the parathyroid adenomas in patients (a) and (b). Left: Subtraction
(Tc-99m-sestamibi minus I-123)-SPECT/CT. Middle: CT. Right: FET-PET/CT. Thin arrows mark
the surgically confirmed location of the parathyroid adenoma. FET: O-2-(18F)fluoroethyl-L-tyrosine;
PET: positron emission tomography; SPECT/CT: single photon emission computed tomography/CT.
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Figure 2. Region-of-interest based analysis of tracer-uptake in the first 60 min after tracer-injection in the
parathyroid adenoma versus neighbouring tissue (thyroid) in patients (a) and (b). Target-to-background
uptake value (TBR, blue) is the ratio between SUVmean (mean standardized uptake value) in the
parathyroid adenoma and SUVmean in the adjacent thyroid tissue.
3. Discussion
This study was purely of an exploratory nature aiming to assess the differential uptake of FET in
parathyroid adenomas versus thyroid tissue in vivo. We found no significant differential FET uptake
in either of the two patients studied.
s ET (another amino acid-derived tracer) shows high uptake in parathyroid adenomas, we had
hypothesised that t is would also be the case for FET. However, the mec anisms of cellular amino
acid uptake are complex, especially with regard to radiolabelled amino acid derivatives such as FET
and MET. Transmembran amino acid uptake is facilitated by an intricate system of specific transport
proteins, all with different affinities for the individual amino acids. Two major subgr ups are the
Na+-dependent and the Na+-independent transpo t system , th latter including the L-type amino
acid tr nsporters (LAT1–4). The exact uptake mechanisms of FET and MET are not clear but it has
been proposed that FET uptake rimarily takes pl c via LAT2 [1], while MET uptake is primarily
mediated by LAT1 [2]. Indeed, an antibody targeting the 4f2/SLC3A2 subunit of LAT1 has been shown
to bind to and to affect parathyroid cells in culture [3], demonstrating th presence of a functional LAT1
receptor in parathyroid tissue. Conve sely, functional LAT2 cell surface expression in parathyroid cells
has no been reported, to our k owledge. These findings ar consistent with th fact that we found
no significant uptake f FET as opposed to that reported on MET in most parathyroid adenomas [4].
It could be argued th t the two adenomas stu ied would also have been negative n MET. We cannot
tot lly rule this out, as we did not pe form MET-PET. However, since the sensitivity of MET-PET for
surgically verified parathyr id adenomas has been found to be above 90%, w find it unlikely that
both adenomas would have een negative on MET-PET.
4. Materials and Methods
This study was entirely exploratory. The primary aim was to study the in vivo uptake of FET in
parathyroid adenomas.
The regional ethics committee for The Capital Region of Copenhagen approved the study
(permission No. H-1-2011-101). After written and oral consent, patients were recruited from an ongoing
study cohort evaluating various imaging modalities in PHP. As a tracer will only be appealing for
clinical use if it provides increased sensitivity compared to the routinely used tracers, we tested
the uptake of FET in two patients—(a) and (b)—with a positive sestamibi-single photon emission
computed tomography/CT (SPECT/CT) performed with dual-isotope subtraction technique, which
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has a reported sensitivity of 93% [5]. The location of the parathyroid adenomas was subsequently
surgically and histologically confirmed. The parathyroid adenomas from patients (a) and (b) weighed
0.83 and 0.22 g, respectively. Preoperative plasma-PTH was 163 and 142 ng/L, respectively.
A dynamic PET/low dose-CT scan of the neck in a single bed-position was initiated immediately
after the injection of 200 MBq FET (Philips Gemini TOF PET/CT). Acquisition continued for 60 min in
list-mode, and counts were re-binned into 5–6 min bins. The exact position of the parathyroid
adenoma was determined by co-registering the subtraction SPECT/CT with the FET PET/CT.
A region-of-interest based target-to-background uptake value (TBR) was calculated as the mean
standardize uptake value (SUVmean) in the parathyroid adenoma divided by SUVmean in the thyroid
tissue in all bins. The bin with the highest TBR (TBRmax) was determined.
5. Conclusions
We found no significant differential FET uptake in parathyroid adenomas, possibly due to lack
of expression of specific transmembrane transporter molecules in parathyroid tissue. 18F-FET seems
therefore not to be a feasible tracer for use in preoperative localisation imaging in PHP.
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